Dr Sands says IMforte’s lower neutropenia rate versus the prior second-line lurbinectedin trial likely reflects allowed primary G-CSF prophylaxis, not an intrinsically safer regimen. The combination still raised anemia, neutropenia, and thrombocytopenia when added to atezolizumab maintenance, so toxicity remains a real tradeoff for patients.
Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.
Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.
Dr Sen says the biggest challenge to lurbinectedin maintenance is Delphi 305, which tests terlatumab plus durvalumab against durvalumab alone after induction chemoimmunotherapy. Its phase 3 results could reshape first-line maintenance before the durvalumab-lurbinectedin question matters, so it is the single key readout to watch.
Dr Sands notes small cell lung cancer scans often show waxing and waning inflammatory findings. That makes a grade 1 radiographic ILD hard to attribute to a B7H3 antibody-drug conjugate; if drug-related ILD is suspected, he says hold the drug, treat aggressively with steroids, and monitor for improvement.
Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.
